Potential role of proton therapy in the treatment of pediatric medulloblastoma/primitive neuro-ectodermal tumors: spinal theca irradiation.
OBJECTIVE
Conventional postoperative photon-beam radiotherapy to the spine in children with medulloblastoma/PNET is associated with severe late effects. This morbidity (growth and developmental) is related to the exit dose of the beams and is particularly severe in young children. With the purpose of reducing this toxicity, a dosimetric study was undertaken in which proton therapy was compared to standard megavoltage photon treatment.


METHODS
The results of a comparative dosimetric study are presented in such a way that the dose distribution achievable with a posterior modulated 100 MeV proton beam (spot scanning method) is compared with that of a standard set of posterior 6 MV x-ray fields. The potential improvements with protons are evaluated, using dose-volume histograms to examine the coverage of the target as well as the dose to the vertebral bodies (growth plates), lungs, heart, and liver.


RESULTS
The target (i.e., the spinal dural sac) received the full prescribed dose in both treatment plans. However, the proportions of the vertebral body volume receiving > or = 50% of the prescribed dose were 100 and 20% for 6 MV x-rays and protons, respectively. For 6 MV x-rays > 60% of the dose prescribed to the target was delivered to 44% of the heart volume, while the proton beam was able to completely avoid the heart, the liver, and in all likelihood the thyroid and gonads as well.


CONCLUSIONS
The present study demonstrates a potential role of proton therapy in decreasing the dose (and toxicity) to the critical structures in the irradiation of the spinal neuraxis in medulloblastoma/PNET. The potential bone marrow and growth arrest sparing effects make this approach specially attractive for intensive chemotherapy protocols and for very young children. Sparing the thyroid gland, the posterior heart wall, and the gonads may be additional advantages in assuring a long-term posttreatment morbidity-free survival.
Miralbell
R
R
Radiation Oncology Department, University Hospital, Geneva, Switzerland.
Lomax
A
A
Russo
M
M
D001932:Brain Neoplasms / Q000532:radiotherapy*; D002528:Cerebellar Neoplasms / Q000532:radiotherapy*; D002675:Child, Preschool; D006128:Growth / Q000528:radiation effects; D006801:Humans; D008527:Medulloblastoma / Q000532:radiotherapy*; D018242:Neuroectodermal Tumors, Primitive / Q000532:radiotherapy*; D061766:Proton Therapy; D011879:Radiotherapy Dosage; D013116:Spinal Cord / Q000528:radiation effects*; D013131:Spine / Q000528:radiation effects*; D011522:Protons
D011522:Protons